Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: Evidence from animal models

Pharmacology and Therapeutics

Volumn 128, Issue 3, 2010, Pages 460-487

  Kehne, John H ^a   Cain, Christopher K ^b,c  

^a Translational Neuropharmacology Consulting   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Animal models; Anxiety; Corticotropin releasing factor; CRF1 receptor; Depression; Stress

Indexed keywords

1 [8 (2,4 DICHLOROPHENYL) 2 METHYLQUINOLIN 4 YL] 1,2,3,6 TETRAHYDROPYRIDIN E 4 CARBOXAMIDE BENZENESULFONATE; 2 (2,4 DICHLOROPHENYL) 4 METHYL 6 (1 PROPYLBUTYL) 7,8 DIHYDRO 6H 1,3,6,8A TETRAAZAACENAPHTHYLENE; 2 [N (2 BROMO 4 ISOPROPYLPHENYL) N ETHYLAMINO] 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 6 METHYLPYRIMIDINE; 3 (4 CHLORO 2 MORPHOLIN 4 YL THIAZOL 5 YL) 8 (1 ETHYLPROPYL) 2,6 DIMETHYL IMIDAZO[1,2 B]PYRIDAZINE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 3,6 DIMETHYL 4 (PENTAN 3 YLOXY) 2 (2,4,6 TRIMETHYLPHENOXY)PYRIDINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; 8 (6 METHOXY 2 METHYLPYRIDIN 3 YL) 2,7 DIMETHYL N [1 METHYLPROPYL]PYRAZOLO[1,5 A] 1,3,5 TRIAZIN 4 AMINE; [4 (3 PENTYLAMINO) 2,7 DIMETHYL 8 (2 METHYL 4 METHOXYPHENYL)PYRAZOLO[1,5ALPHA]PYRIMIDINE]; [N CYCLOPROPYLMETHYL 2,5 DIMETHYL N PROPYL N' (2,4,6 TRICHLOROPHENYL)PYRIMIDINE 4,6 DIAMINE]; ANTALARMIN; BMS 562086; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CP 316311; CRA 0450; DMP 904; ESCITALOPRAM; GSK 561679; GSK 586529; GW 876008; MJL 11092; N,N BIS(2 METHOXYETHYL) 3 (4 METHOXY 2 METHYLPHENYL) 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDIN 7 AMINE; NBI 34041; NBI 3B1996; ONO 2333MS; PF 572778; PLACEBO; PYRAZOLO[1,5 A] 1,3,5 TRIAZIN 4 AMINE,8 [4 (BROMO)2 CHLOROPHENYL] N, N BIS(2 METHOXYETHYL) 2,7 DIMETHYL (9 CHLORIDE); R 27899; R 317573; UNCLASSIFIED DRUG;

ACUTE STRESS; ADDICTION; ALCOHOLISM; CHRONIC STRESS; CLINICAL TRIAL; DEPRESSION; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEAR; FORCED SWIMMING TEST; FREEZING; GENERALIZED ANXIETY DISORDER; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IRRITABLE COLON; LEARNED HELPLESSNESS; MAJOR DEPRESSION; MAZE TEST; MENTAL STRESS; MOOD DISORDER; NEUROPATHOLOGY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PHENOTYPE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SOCIAL PHOBIA; STARTLE REFLEX; TRANQUILIZING ACTIVITY; WITHDRAWAL SYNDROME;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS, PSYCHOLOGICAL;

EID: 78049284816     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.08.011     Document Type: Review

References (247)

1. Adamec R., Fougere D., Risbrough V. CRF receptor blockade prevents initiation and consolidation of stress effects on affect in the predator stress model of PTSD. Int J Neuropsychopharmacol 2010, 13:747-757.
2. Aguilera G., Nikodemova M., Wynn P.C., Catt K.J. Corticotropin releasing hormone receptors: two decades later. Peptides 2004, 25:319-329.
3. Alonso R., Griebel G., Pavone G., Stemmelin J., Le Fur G., Soubrie P. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry 2004, 9(278-286):224.
4. Altemus M., Pigott T., Kalogeras K.T., Demitrack M., Dubbert B., Murphy D.L., et al. Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch Gen Psychiatry 1992, 49:9-20.
5. Amat J., Baratta M.V., Paul E., Bland S.T., Watkins L.R., Maier S.F. Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat Neurosci 2005, 8:365-371.
6. Arborelius L., Skelton K.H., Thrivikraman K.V., Plotsky P.M., Schulz D.W., Owens M.J. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154, 526: behavioral, endocrine and neurochemical effects in the rat. J Pharmacol Exp Ther 2000, 294:588-597.
7. Austin M.C., Janosky J.E., Murphy H.A. Increased corticotropin-releasing hormone immunoreactivity in monoamine-containing pontine nuclei of depressed suicide men. Mol Psychiatry 2003, 8:324-332.
8. Bailey J.E., Argyropoulos S.V., Kendrick A.H., Nutt D.J. Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers. Depress Anxiety 2005, 21:18-25.
9. Bailey J.E., Argyropoulos S.V., Lightman S.L., Nutt D.J. Does the brain noradrenaline network mediate the effects of the CO2 challenge?. J Psychopharmacol 2003, 17:252-259.
10. Bailey J.E., Kendrick A., Diaper A., Potokar J.P., Nutt D.J. A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers. J Psychopharmacol 2007, 21:42-49.
11. Bailey J.E., Nutt D.J. GABA-A receptors and the response to CO(2) inhalation-a translational trans-species model of anxiety?. Pharmacol Biochem Behav 2008, 90:51-57.
12. Bakish D. The patient with comorbid depression and anxiety: the unmet need. J Clin Psychiatry 1999, 60:20-24.
13. Bakshi V.P., Smith-Roe S., Newman S.M., Grigoriadis D.E., Kalin N.H. Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRH2) receptors in lateral septum or CRH1 receptors in amygdala. J Neurosci 2002, 22:2926-2935.
14. Bale T.L., Vale W.W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 2004, 44:525-557.
15. Baratta M.V., Christianson J.P., Gomez D.M., Zarza C.M., Amat J., Masini C.V., et al. Controllable versus uncontrollable stressors bi-directionally modulate conditioned but not innate fear. Neuroscience 2007, 146:1495-1503.
16. Baratta M.V., Lucero T.R., Amat J., Watkins L.R., Maier S.F. Role of the ventral medial prefrontal cortex in mediating behavioral control-induced reduction of later conditioned fear. Learn Mem 2008, 15:84-87.
17. Barlow D.H., Chorpita B.F., Turovsky J. Fear, panic, anxiety, and disorders of emotion. Nebr Symp Motiv 1996, 43:251-328.
18. Belanoff J.K., Kalehzan M., Sund B., Fleming Ficek S.K., Schatzberg A.F. Cortisol activity and cognitive changes in psychotic major depression. Am J Psychiatry 2001, 158:1612-1616.
19. Binder E.B., Nemeroff C.B. The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry 2010, 15:574-588.
20. Binder E.B., Owens M.J., Liu W., Deveau T.C., Rush A.J., Trivedi M.H., et al. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry 2010, 67:369-379.
21. Binneman B., Feltner D., Kolluri S., Shi Y., Qiu R., Stiger T. A 6-week randomized, placebo-controlled trial of CP-316, 311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 2008, 165:617-620.
22. Bissette G., Klimek V., Pan J., Stockmeier C., Ordway G. Elevated concentrations of CRF in the locus coeruleus of depressed subjects. Neuropsychopharmacology 2003, 28:1328-1335.
23. Blanchard R.J., Blanchard D.C. Crouching as an index of fear. J Comp Physiol Psychol 1969, 67.
24. Blanchard R.J., Blanchard D.C. Defensive reactions in the albino rat. Learn Motiv 1971, 2:351-362.
25. Blanchard R.J., Fukunaga K.K., Blanchard D.C. Environmental control of defensive reaction to footshock. Bulletin of the Psychonomic Society 1976, 8:129-130.
26. Blanchard R.J., Mast M., Blanchard D.C. Stimulus control of defensive reactions in the albino rat. J Comp Physiol Psychol 1975, 88:81-88.
27. Blanchard R.J., Yudko E.B., Rodgers R.J., Blanchard D.C. Defense system psychopharmacology: an ethological approach to the pharmacology of fear and anxiety. Behav Brain Res 1993, 58:155-166.
28. Blank T., Nijholt I., Vollstaedt S., Spiess J. The corticotropin-releasing factor receptor 1 antagonist CP-154, 526 reverses stress-induced learning deficits in mice. Behav Brain Res 2003, 138:207-213.
29. Bolles R.C. Species-specific defense reactions and avoidance learning. Psychol Rev 1970, 77:32-48.
30. Bradley R.G., Binder E.B., Epstein M.P., Tang Y., Nair H.P., Liu W., et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry 2008, 65:190-200.
31. Bremner J.D. Stress and brain atrophy. CNS Neurol Disord Drug Targets 2006, 5:503-512.
32. Bremner J.D., Brett E. Trauma-related dissociative states and long-term psychopathology in posttraumatic stress disorder. J Trauma Stress 1997, 10:37-49.
33. Broadbear J.H., Winger G., Rivier J.E., Rice K.C., Woods J.H. Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys. Neuropsychopharmacology 2004, 29:1112-1121.
34. Cain C.K., Blouin A.M., Barad M. Temporally massed CS presentations generate more fear extinction than spaced presentations. J Exp Psychol Anim Behav Process 2003, 29:323-333.
35. Cain, C.K., LeDoux, J.E. (2008). Cain CK, LeDoux JE (2008) Brain mechanisms of Pavlovian and instrumental aversive conditioning. In: Handbook of Anxiety and Fear (Nutt DJ, Blanchard RJ, Blanchard DC, Griebel G, eds), pp 103-125. Amsterdam: Elsevier Academic Press. In D. J. Nutt, R. J. Blanchard, D. C. Blanchard & G. Griebel (Eds.), Handbook of Anxiety and Fear (pp. 103-125). Amsterdam: Elsevier Academic Press.
36. Campbell B.M., Morrison J.L., Walker E.L., Merchant K.M. Differential regulation of behavioral, genomic, and neuroendocrine responses by CRF infusions in rats. Pharmacol Biochem Behav 2004, 77:447-455.
37. Chaki S., Nakazato A., Kennis L., Nakamura M., Mackie C., Sugiura M., et al. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur J Pharmacol 2004, 485:145-158.
38. Chaki S., Okuyama S., Nakazato A., Kumagai T., Okubo T., Ikeda Y., et al. In vitro pharmacological profile of nonpeptide CRF1 receptor antagonists, CRA1000 and CRA1001. Eur J Pharmacol 1999, 371:205-211.
39. Charney D.S. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand Suppl 2003, 38-50.
40. Charney D.S. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. Am J Psychiatry 2004, 161:195-216.
41. Charney D.S., Deutch A. A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit Rev Neurobiol 1996, 10:419-446.
42. Chen C., Dagnino R., De Souza E.B., Grigoriadis D.E., Huang C.Q., Kim K.-I., et al. Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J Med Chem 1996, 39:4358-4360.
43. Cole B.J., Koob G.F. Propranolol antagonizes the enhanced conditioned fear produced by corticotropin releasing factor. J Pharmacol Exp Ther 1988, 247:902-910.
44. Conrad C.D., LeDoux J.E., Magarinos A.M., McEwen B.S. Repeated restraint stress facilitates fear conditioning independently of causing hippocampal CA3 dendritic atrophy. Behav Neurosci 1999, 113:902-913.
45. Cook C.J. Stress induces CRF release in the paraventricular nucleus, and both CRF and GABA release in the amygdala. Physiol Behav 2004, 82:751-762.
46. Cordero M.I., Venero C., Kruyt N.D., Sandi C. Prior exposure to a single stress session facilitates subsequent contextual fear conditioning in rats. Evidence for a role of corticosterone. Horm Behav 2003, 44:338-345.
47. Coric V., Feldman H.H., Oren D.A., Shekhar A., Pultz J., Dockens R.C., et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 2010, 27:417-425.
48. Davis M., Barad M., Otto M., Southwick S. Combining pharmacotherapy with cognitive behavioral therapy: traditional and new approaches. J Trauma Stress 2006, 19:571-581.
49. Davis M., Myers K.M., Chhatwal J., Ressler K.J. Pharmacological treatments that facilitate extinction of fear: relevance to psychotherapy. NeuroRx 2007, 3:82-96.
50. Davis M., Walker D.L., Lee Y. Amygdala and bed nucleus of the stria terminalis: differential roles in fear and anxiety measured with the acoustic startle reflex. Philos Trans R Soc Lond B Biol Sci 1997, 352:1675-1687.
51. Davis M., Walker D.L., Lee Y. Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Possible relevance to PTSD. Ann N Y Acad Sci 1997, 821:305-331.
52. Dawe G.S., Huff K.D., Vandergriff J.L., Sharp T., O'Neill M.J., Rasmussen K. Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity. Biol Psychiatry 2001, 50:510-520.
53. Dawson G.R., Bailey J.E., Papadopoulos A., Diaper A., Phillips S.M., van der Ark P., et al. Preliminary evidence of efficacy of a CRF1 receptor antagonist in the 7.5% CO2 model of anxiety. Society for Neuroscience 2009, Society for Neuroscience, Chicago IL, (pp. Abstract 250.255).
54. de Jongh R., Groenink L., van der Gugten J., Olivier B. Light-enhanced and fear-potentiated startle: temporal characteristics and effects of alpha-helical corticotropin-releasing hormone. Biol Psychiatry 2003, 54:1041-1048.
55. Deak T., Nguyen K.T., Ehrlich A.L., Watkins L.R., Spencer R.L., Maier S.F., et al. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 1999, 140:79-86.
56. Debiec J., Doyere V., Nader K., Ledoux J.E. Directly reactivated, but not indirectly reactivated, memories undergo reconsolidation in the amygdala. Proc Natl Acad Sci USA 2006, 103:3428-3433.
57. Diergaarde L., Schoffelmeer A.N., De Vries T.J. Beta-adrenoceptor mediated inhibition of long-term reward-related memory reconsolidation. Behav Brain Res 2006, 170:333-336.
58. Ducottet C., Griebel G., Belzung C. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:625-631.
59. Fanselow M.S. Conditional and unconditional components of postshock freezing. Pavlov J Biol Sci 1980, 15:177-182.
60. Fanselow M.S. Associative vs topographical accounts of the immediate shock-freezing deficit in rats: Implication for the response selection rules governing species-specific defensive reactions. Learning and Motivation 1986, 17:16-39.
61. Fanselow M.S. Factors governing one-trial contextual conditioning. Animal Learning & Behavior 1990, 18:264-270.
62. Fanselow M.S. The midbrain periaqueductal gray as a coordinator of action in response to fear and anxiety. The Midbrain Periaqueductal Grey Matter: Functional, Anatomical and Immunohistochemical Organization 1991, Plenum Publishing Corp, New York. A. Depaulis, R. Bandler (Eds.).
63. Fanselow, M. S., & Lester, L. S. (1988). A functional behavioristic approach to aversively motivated behavior: Predatory imminence as a determinant of the topography of defensive behavior. In R. C. Bolles, M. D. Beecher (Eds.), Evolution and Learning, Erlbaum: Hillsdale NJ, pp. 185-211.
64. Fanselow M.S., Poulos A.M. The neuroscience of mammalian associative learning. Annu Rev Psychol 2005, 56:207-234.
65. Fossey M.D., Lydiard R.B., Ballenger J.C., Laraia M.T., Bissette G., Nemeroff C.B. Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol Psychiatry 1996, 39:703-707.
66. Fox N.A., Henderson H.A., Marshall P.J., Nichols K.E., Ghera M.M. Behavioral inhibition: linking biology and behavior within a developmental framework. Annu Rev Psychol 2005, 56:235-262.
67. Funk D., Li Z., Le A.D. Effects of environmental and pharmacological stressors on c-fos and corticotropin-releasing factor mRNA in rat brain: relationship to the reinstatement of alcohol seeking. Neuroscience 2006, 138:235-243.
68. Gallagher J.P., Orozco-Cabal L.F., Liu J., Shinnick-Gallagher P. Synaptic physiology of central CRH system. Eur J Pharmacol 2008, 583:215-225.
69. Gehlert D.R., Cippitelli A., Thorsell A., Le A.D., Hipskind P.A., Hamdouchi C., et al. 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2, 6-dimethyl-imidazo[1, 2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci 2007, 27:2718-2726.
70. Gehlert D.R., Shekhar A., Morin S.M., Hipskind P.A., Zink C., Gackenheimer S.L., et al. Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor. Eur J Pharmacol 2005, 509:145-153.
71. Goeders N.E., Clampitt D.M. Potential role for the hypothalamo-pituitary-adrenal axis in the conditioned reinforcer-induced reinstatement of extinguished cocaine seeking in rats. Psychopharmacology (Berl) 2002, 161:222-232.
72. Gold P.E. The many faces of amnesia. Learn Mem 2006, 13:506-514.
73. Gold P.W., Chrousos G.P. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc Assoc Am Physicians 1999, 111:22-34.
74. Gold P.W., Chrousos G.P. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002, 7:254-275.
75. Gold P.W., Gabry K.E., Yasuda M.R., Chrousos G.P. Divergent endocrine abnormalities in melancholic and atypical depression: clinical and pathophysiologic implications. Endocrinol Metab Clin North Am 2002, 31:37-62. vi.
76. Grigoriadis D.E. The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. Expert Opin Ther Targets 2005, 9:651-684.
77. Gully D., Geslin M., Serva L., Fontaine E., Roger P., Lair C., et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization. J Pharmacol Exp Ther 2002, 301:322-332.
78. Gutman D.A., Coyer M.J., Boss-Williams K.A., Owens M.J., Nemeroff C.B., Weiss J.M. Behavioral effects of the CRF1 receptor antagonist R121919 in rats selectively bred for high and low activity in the swim test. Psychoneuroendocrinology 2008, 33:1093-1101.
79. Gutman D.A., Owens M.J., Skelton K.H., Thrivikraman K.V., Nemeroff C.B. The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J Pharmacol Exp Ther 2003, 304:874-880.
80. Hammack S.E., Pepin J.L., DesMarteau J.S., Watkins L.R., Maier S.F. Low doses of corticotropin-releasing hormone injected into the dorsal raphe nucleus block the behavioral consequences of uncontrollable stress. Behav Brain Res 2003, 147:55-64.
81. Hammack S.E., Richey K.J., Watkins L.R., Maier S.F. Chemical lesion of the bed nucleus of the stria terminalis blocks the behavioral consequences of uncontrollable stress. Behav Neurosci 2004, 118:443-448.
82. Hansson A.C., Cippitelli A., Sommer W.H., Fedeli A., Bjork K., Soverchia L., et al. Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. Proc Natl Acad Sci USA 2006, 103:15236-15241.
83. Hatzinger M. Neuropeptides and the hypothalamic-pituitary-adrenocortical (HPA) system: review of recent research strategies in depression. World J Biol Psychiatry 2000, 1:105-111.
84. Hauger R.L., Risbrough V., Brauns O., Dautzenberg F.M. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets 2006, 5:453-479.
85. Heilig M., Koob G.F. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 2007, 30:399-406.
86. Heim C., Plotsky P.M., Nemeroff C.B. Importance of studying the contributions of early adverse experience to neurobiological findings in depression. Neuropsychopharmacology 2004, 29:641-648.
87. Heinrichs S.C., De Souza E.B., Schulteis G., Lapsansky J.L., Grigoriadis D.E. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 2002, 27:194-202.
88. Hikichi T., Akiyoshi J., Yamamoto Y., Tsutsumi T., Isogawa K., Nagayama H. Suppression of conditioned fear by administration of CRF receptor antagonist CP-154, 526. Pharmacopsychiatry 2000, 33:189-193.
89. Hillhouse E.W., Grammatopoulos D.K. The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 2006, 27:260-286.
90. Ho S.P., Takahashi L.K., Livanov V., Spencer K., Lesher T., Maciag C., et al. Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor. Brain Res Mol Brain Res 2001, 89:29-40.
91. Hodgson R.A., Higgins G.A., Guthrie D.H., Lu S.X., Pond A.J., Mullins D.E., et al. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. Pharmacol Biochem Behav 2007, 86:431-440.
92. Howard O., Carr G.V., Hill T.E., Valentino R.J., Lucki I. Differential blockade of CRF-evoked behaviors by depletion of norepinephrine and serotonin in rats. Psychopharmacology (Berl) 2008, 199:569-582.
93. Hubbard D.T., Nakashima B.R., Lee I., Takahashi L.K. Activation of basolateral amygdala corticotropin-releasing factor 1 receptors modulates the consolidation of contextual fear. Neuroscience 2007, 150:818-828.
94. Iijima M., Chaki S. Separation-induced ultrasonic vocalization in rat pups: further pharmacological characterization. Pharmacol Biochem Behav 2005, 82:652-657.
95. Ise S., Nagano N., Okuda S., Ohta H. Corticotropin-releasing factor modulates maternal separation-induced ultrasonic vocalization in rat pups via activation of CRF1 receptor. Brain Res 2008, 1234:59-65.
96. Ising M., Zimmermann U.S., Kunzel H.E., Uhr M., Foster A.C., Learned-Coughlin S.M., et al. High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 2007, 32:1941-1949.
97. Ji G., Fu Y., Ruppert K.A., Neugebauer V. Pain-related anxiety-like behavior requires CRF1 receptors in the amygdala. Mol Pain 2007, 3:13.
98. Ji G., Neugebauer V. Differential effects of CRF1 and CRF2 receptor antagonists on pain-related sensitization of neurons in the central nucleus of the amygdala. J Neurophysiol 2007.
99. Jutkiewicz E.M., Wood S.K., Houshyar H., Hsin L.W., Rice K.C., Woods J.H. The effects of CRF antagonists, antalarmin, CP154, 526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology (Berl) 2005, 180:215-223.
100. Kasckow J.W., Baker D., Geracioti T.D. Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides 2001, 22:845-851.
101. Keck M.E., Kern N., Erhardt A., Unschuld P.G., Ising M., Salyakina D., et al. Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am J Med Genet B Neuropsychiatr Genet 2008.
102. Keck M.E., Welt T., Wigger A., Renner U., Engelmann M., Holsboer F., et al. The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 2001, 13:373-380.
103. Kehne J.H. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol Disord Drug Targets 2007, 6:163-182.
104. Kehne J.H., Baron B.M., Harrison B.L., McCloskey T.C., Palfreyman M.G., Poirot M., et al. MDL 100, 458 and MDL 102, 288: two potent and selective glycine receptor antagonists with different functional profiles. Eur J Pharmacol 1995, 284:109-118.
105. Kehne J.H., Coverdale S., McCloskey T.C., Hoffman D.C., Cassella J.V. Effects of the CRF(1) receptor antagonist, CP 154, 526, in the separation-induced vocalization anxiolytic test in rat pups. Neuropharmacology 2000, 39:1357-1367.
106. Kehne J.H., De Lombaert S. Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders. Curr Drug Targets CNS Neurol Disord 2002, 1:467-493.
107. Kehne J.H., Maynard G.D. CRF1 receptor antagonists: treatment of stress-related disorders. Drug Discovery Today: Therapeutic Strategies 2008, online publication.
108. Kehne J.H., McCloskey T.C., Baron B.M., Chi E.M., Harrison B.L., Whitten J.P., et al. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations. Eur J Pharmacol 1991, 193:283-292.
109. Kellner M., Schick M., Yassouridis A., Struttmann T., Wiedemann K., Alm B. Metyrapone tests in patients with panic disorder. Biol Psychiatry 2004, 56:898-900.
110. Knapp D.J., Overstreet D.H., Moy S.S., Breese G.R. SB242084, flumazenil, and CRA1000 block ethanol withdrawal-induced anxiety in rats. Alcohol 2004, 32:101-111.
111. Koob G.F. Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 1999, 46:1167-1180.
112. Koob G.F. Alcoholism, corticotropin-releasing factor, and molecular genetic allostasis. Biol Psychiatry 2008, 63:137-138.
113. Koob G.F. Corticotropin-releasing factor, neuroplasticity (sensitization), and alcoholism. Proc Natl Acad Sci USA 2008, 105:8809-8810.
114. Lang P.J., Davis M., Ohman A. Fear and anxiety: animal models and human cognitive psychophysiology. J Affect Disord 2000, 61:137-159.
115. LeDoux J. Emotional networks and motor control: a fearful view. Prog Brain Res 1996, 107:437-446.
116. LeDoux J.E. Emotion circuits in the brain. Annu Rev Neurosci 2000, 23:155-184.
117. Lehner M., Taracha E., Skorzewska A., Turzynska D., Sobolewska A., Maciejak P., et al. Expression of c-Fos and CRF in the brains of rats differing in the strength of a fear response. Behav Brain Res 2008, 188:154-167.
118. Lelas S., Wong H., Li Y.W., Heman K.L., Ward K.A., Zeller K.L., et al. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2, 7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1, 5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats. J Pharmacol Exp Ther 2004, 309:293-302.
119. Lelas S., Zeller K.L., Ward K.A., McElroy J.F. The anxiolytic CRF(1) antagonist DMP696 fails to function as a discriminative stimulus and does not substitute for chlordiazepoxide in rats. Psychopharmacology (Berl) 2003, 166:408-415.
120. Li Y.W., Fitzgerald L., Wong H., Lelas S., Zhang G., Lindner M.D., et al. The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists. CNS Drug Rev 2005, 11:21-52.
121. Li Y.W., Hill G., Wong H., Kelly N., Ward K., Pierdomenico M., et al. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy. J Pharmacol Exp Ther 2003, 305:86-96.
122. Louis C., Cohen C., Depoortere R., Griebel G. Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72s schedule in the rat. Neuropsychopharmacology 2006, 31:2180-2187.
123. Lu L., Liu Z., Huang M., Zhang Z. Dopamine-dependent responses to cocaine depend on corticotropin-releasing factor receptor subtypes. J Neurochem 2003, 84:1378-1386.
124. Lydiard R.B. Irritable bowel syndrome, anxiety, and depression: what are the links?. J Clin Psychiatry 2001, 62(Suppl 8):38-45. discussion 46-37.
125. Lydiard R.B. Increased prevalence of functional gastrointestinal disorders in panic disorder: clinical and theoretical implications. CNS Spectr 2005, 10:899-908.
126. Lydiard R.B. Worried sick: antidepressants, stress, and inflammation. J Clin Psychiatry 2007, 68:1613-1614.
127. Maciag C.M., Dent G., Gilligan P., He L., Dowling K., Ko T., et al. Effects of a non-peptide CRF antagonist (DMP696) on the behavioral and endocrine sequelae of maternal separation. Neuropsychopharmacology 2002, 26:574-582.
128. Maier S.F., Watkins L.R. Stressor controllability and learned helplessness: the roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci Biobehav Rev 2005, 29:829-841.
129. Majchrzak M., Ferry B., Marchand A.R., Herbeaux K., Seillier A., Barbelivien A. Entorhinal cortex lesions disrupt fear conditioning to background context but spare fear conditioning to a tone in the rat. Hippocampus 2006, 16:114-124.
130. Mallo T., Berggard C., Eller M., Damberg M., Oreland L., Harro J. Effect of long-term blockade of CRF(1) receptors on exploratory behaviour, monoamines and transcription factor AP-2. Pharmacol Biochem Behav 2004, 77:855-865.
131. Maniam J., Morris M.J. Long-term postpartum anxiety and depression-like behavior in mother rats subjected to maternal separation are ameliorated by palatable high fat diet. Behav Brain Res 2010, 208:72-79.
132. Mansbach R.S., Brooks E.N., Chen Y.L. Antidepressant-like effects of CP-154, 526, a selective CRF1 receptor antagonist. Eur J Pharmacol 1997, 323:21-26.
133. Maren S. Neurobiology of Pavlovian fear conditioning. Annu Rev Neurosci 2001, 24:897-931.
134. Marks I. Fears, phobias, and rituals. Panic, Anxiety and Their Disorders 1987, Oxford University Press, New York.
135. Martinez V., Tache Y. CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr Pharm Des 2006, 12:4071-4088.
136. Mayer E.A., Berman S., Suyenobu B., Labus J., Mandelkern M.A., Naliboff B.D., et al. Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain 2005, 115:398-409.
137. McElroy J.F., Ward K.A., Zeller K.L., Jones K.W., Gilligan P.J., He L., et al. The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats. Psychopharmacology (Berl) 2002, 165:86-92.
138. McEwen B.S. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 2005, 54:20-23.
139. McEwen B.S. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007, 87:873-904.
140. McEwen B.S. Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol 2008, 583:174-185.
141. McGaugh J.L. Memory-a century of consolidation. Science 2000, 287:248-251.
142. Merali Z., Du L., Hrdina P., Palkovits M., Faludi G., Poulter M.O., et al. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 2004, 24:1478-1485.
143. Merali Z., Kent P., Du L., Hrdina P., Palkovits M., Faludi G., et al. Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biol Psychiatry 2006, 59:594-602.
144. Miles L.A., Walker D., Davis M. Corticotropin-releasing factor (CRF) type 1 receptors in the bed nucleus of the stria terminalis (BNST) mediate long- (minutes) but not short- (seconds) duration startle increases to shock-predicting cues. Society for Neuroscience Annual Meeting. Washington, D. C 2008.
145. Millan M.J., Brocco M., Gobert A., Dorey G., Casara P., Dekeyne A. Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154, 526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology 2001, 25:585-600.
146. Moriceau S., Raineki C., Holman J.D., Holman J.G., Sullivan R.M. Enduring neurobehavioral effects of early life trauma mediated through learning and corticosterone suppression. Front Behav Neurosci 2009, 3:22.
147. Moriceau S., Shionoya K., Jakubs K., Sullivan R.M. Early-life stress disrupts attachment learning: the role of amygdala corticosterone, locus ceruleus corticotropin releasing hormone, and olfactory bulb norepinephrine. J Neurosci 2009, 29:15745-15755.
148. Nader K., Schafe G.E., Le Doux J.E. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature 2000, 406:722-726.
149. Nalivaiko E., Blessing W.W. CRF1-receptor antagonist CP-154526 reduces alerting-related cutaneous vasoconstriction in conscious rabbits. Neuroscience 2003, 117:129-138.
150. Nalivaiko E., Blessing W.W. CRF1 receptor antagonist CP-154, 526 reduces cardiovascular responses during acute psychological stress in rabbits. Brain Res 2004, 1017:234-237.
151. Nemeroff C.B. Clinical significance of psychoneuroendocrinology in psychiatry: focus on the thyroid and adrenal. J Clin Psychiatry 1989, 50:13-20. Suppl, discussion 21-12.
152. Nemeroff C.B. New vistas in neuropeptide research in neuropsychiatry: focus on corticotropin-releasing factor. Neuropsychopharmacology 1992, 6:69-75.
153. Nemeroff C.B. New directions in the development of antidepressants: the interface of neurobiology and psychiatry. Hum Psychopharmacol 2002, 17(Suppl 1):S13-16.
154. Nemeroff C.B. Early-life adversity, CRF dysregulation, and vulnerability to mood and anxiety disorders. Psychopharmacol Bull 2004, 38(Suppl 1):14-20.
155. Nemeroff C.B. Neurobiological consequences of childhood trauma. J Clin Psychiatry 2004, 65(Suppl 1):18-28.
156. Nemeroff C.B., Bremner J.D., Foa E.B., Mayberg H.S., North C.S., Stein M.B. Posttraumatic stress disorder: a state-of-the-science review. J Psychiatr Res 2006, 40:1-21.
157. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984, 226:1342-1344.
158. Newport D.J., Heim C., Owens M.J., Ritchie J.C., Ramsey C.H., Bonsall R., et al. Cerebrospinal fluid corticotropin-releasing factor (CRF) and vasopressin concentrations predict pituitary response in the CRF stimulation test: a multiple regression analysis. Neuropsychopharmacology 2003, 28:569-576.
159. Nielsen D.M., Carey G.J., Gold L.H. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. Eur J Pharmacol 2004, 499:135-146.
160. Ohata H., Arai K., Shibasaki T. Effect of chronic administration of a CRF(1) receptor antagonist, CRA1000, on locomotor activity and endocrine responses to stress. Eur J Pharmacol 2002, 457:201-206.
161. Ohman A., Mineka S. Fears, phobias, and preparedness: toward an evolved module of fear and fear learning. Psychol Rev 2001, 108:483-522.
162. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S., Nakazato A., et al. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp Ther 1999, 289:926-935.
163. O'Malley D., Dinan T.G., Cryan J.F. Alterations in colonic corticotropin-releasing factor receptors in the maternally separated rat model of irritable bowel syndrome: differential effects of acute psychological and physical stressors. Peptides 2010, 31:662-670.
164. O'Malley D., Dinan T.G., Cryan J.F. Neonatal maternal separation in the rat impacts on the stress responsivity of central corticotropin-releasing factor receptors in adulthood. Psychopharmacology (Berl) 2010.
165. Overstreet D.H., Griebel G. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol 2004, 497:49-53.
166. Overstreet D.H., Keeney A., Hogg S. Antidepressant effects of citalopram and CRF receptor antagonist CP-154, 526 in a rat model of depression. Eur J Pharmacol 2004, 492:195-201.
167. Overstreet D.H., Knapp D.J., Breese G.R. Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors. Pharmacol Biochem Behav 2004, 77:405-413.
168. Pelleymounter M.A., Joppa M., Carmouche M., Cullen M.J., Brown B., Murphy B., et al. Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF. J Pharmacol Exp Ther 2000, 293:799-806.
169. Pelleymounter M.A., Joppa M., Ling N., Foster A.C. Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. J Pharmacol Exp Ther 2002, 302:145-152.
170. Pelleymounter M.A., Joppa M., Ling N., Foster A.C. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 2004, 25:659-666.
171. Perrin M.H., Vale W.W. Corticotropin releasing factor receptors and their ligand family. Ann NY Acad Sci 1999, 885:312-328.
172. Phillips R.G., LeDoux J.E. Lesions of the dorsal hippocampal formation interfere with background but not foreground contextual fear conditioning. Learn Mem 1994, 1:34-44.
173. Pitman R.K., Delahanty D.L. Conceptually driven pharmacologic approaches to acute trauma. CNS Spectr 2005, 10:99-106.
174. Pitts M.W., Todorovic C., Blank T., Takahashi L.K. The central nucleus of the amygdala and corticotropin-releasing factor: insights into contextual fear memory. J Neurosci 2009, 29:7379-7388.
175. Radulovic J., Ruhmann A., Liepold T., Spiess J. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci 1999, 19:5016-5025.
176. Rau V., DeCola J.P., Fanselow M.S. Stress-induced enhancement of fear learning: an animal model of posttraumatic stress disorder. Neurosci Biobehav Rev 2005, 29:1207-1223.
177. Rau V., Fanselow M.S. Neurobiological and neuroethological perspectives on fear and anxiety. Understanding Trauma: Integrating Biological, Clinical, and Cultural Perspectives 2007, 27-40. Cambridge University Press, New York. L.J. Kirmayer, R. Lemelson, M. Barad (Eds.).
178. Rau V., Fanselow M.S. Exposure to a stressor produces a long lasting enhancement of fear learning in rats. Stress 2008, 1.
179. Richardson H.N., Zhao Y., Fekete E.M., Funk C.K., Wirsching P., Janda K.D., et al. MPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF(1)) antagonist. Pharmacol Biochem Behav 2008, 88:497-510.
180. Risbrough V.B., Geyer M.A., Hauger R.L., Coste S., Stenzel-Poore M., Wurst W., et al. CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues. Neuropsychopharmacology 2008, 34:1494-1503.
181. Risbrough V.B., Hauger R.L., Pelleymounter M.A., Geyer M.A. Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl) 2003, 170:178-187.
182. Rosen J.B. The neurobiology of conditioned and unconditioned fear: a neurobehavioral system analysis of the amygdala. Behav Cogn Neurosci Rev 2004, 3:23-41.
183. Sagami Y., Shimada Y., Tayama J., Nomura T., Satake M., Endo Y., et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004, 53:958-964.
184. Sajdyk T.J., Schober D.A., Gehlert D.R., Shekhar A. Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. Behav Brain Res 1999, 100:207-215.
185. Sananbenesi F., Fischer A., Schrick C., Spiess J., Radulovic J. Mitogen-activated protein kinase signaling in the hippocampus and its modulation by corticotropin-releasing factor receptor 2: a possible link between stress and fear memory. J Neurosci 2003, 23:11436-11443.
186. Sandi C., Merino J.J., Cordero M.I., Touyarot K., Venero C. Effects of chronic stress on contextual fear conditioning and the hippocampal expression of the neural cell adhesion molecule, its polysialylation, and L1. Neuroscience 2001, 102:329-339.
187. Sapolsky R.M. Glucocorticoids, stress, and their adverse neurological effects: relevance to aging. Exp Gerontol 1999, 34:721-732.
188. Sapolsky R.M. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000, 57:925-935.
189. Sapolsky R.M. Atrophy of the hippocampus in posttraumatic stress disorder: how and when?. Hippocampus 2001, 11:90-91.
190. Sapolsky R.M. Stress and plasticity in the limbic system. Neurochem Res 2003, 28:1735-1742.
191. Sarnyai Z. Neurobiology of stress and cocaine addiction. Studies on corticotropin-releasing factor in rats, monkeys, and humans. Ann NY Acad Sci 1998, 851:371-387.
192. Sarnyai Z., Biro E., Gardi J., Vecsernyes M., Julesz J., Telegdy G. Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res 1995, 675:89-97.
193. Sarnyai Z., Shaham Y., Heinrichs S.C. The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 2001, 53:209-243.
194. Saunders J., Williams J.P. New developments in the study of corticotropin releasing factor. Annu Rep Med Chem 2001, 36:21-30.
195. Sautter F.J., Bissette G., Wiley J., Manguno-Mire G., Schoenbachler B., Myers L., et al. Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol Psychiatry 2003, 54:1382-1388.
196. Schatzberg A.F. New approaches to managing psychotic depression. J Clin Psychiatry 2003, 64(Suppl 1):19-23.
197. Schmidt M.E., Andrews R.D., van der Ark P., Brown T., Mannaert E., Steckler T., et al. Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology (Berl) 2010, 208:109-119.
198. Schulz D.W., Mansbach R.S., Sprouse J., Braselton J.P., Collins J., Corman M., et al. CP-154, 526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 1996, 93:10477-10482.
199. Schwartz C.E., Wright C.I., Shin L.M., Kagan J., Rauch S.L. Inhibited and uninhibited infants "grown up": adult amygdalar response to novelty. Science 2003, 300:1952-1953.
200. Sekino A., Ohata H., Mano-Otagiri A., Arai K., Shibasaki T. Both corticotropin-releasing factor receptor type 1 and type 2 are involved in stress-induced inhibition of food intake in rats. Psychopharmacology (Berl) 2004, 176:30-38.
201. Seligman M.E.P. Phobias and preparedness. Behav Ther 1971, 2:307-320.
202. Selye H. Implications of stress concept. NY State J Med 1975, 75:2139-2145.
203. Seymour P.A., Schmidt A.W., Schulz D.W. The pharmacology of CP-154, 526, a non-peptide antagonist of the CRH1 receptor: a review. CNS Drug Rev 2003, 9:57-96.
204. Sherman J.E., Kalin N.H. ICV-CRH alters stress-induced freezing behavior without affecting pain sensitivity. Pharmacol Biochem Behav 1988, 30:801-807.
205. Smoller J.W., Rosenbaum J.F., Biederman J., Kennedy J., Dai D., Racette S.R., et al. Association of a genetic marker at the corticotropin-releasing hormone locus with behavioral inhibition. Biol Psychiatry 2003, 54:1376-1381.
206. Smoller J.W., Yamaki L.H., Fagerness J.A., Biederman J., Racette S., Laird N.M., et al. The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder. Biol Psychiatry 2005, 57:1485-1492.
207. Sommer W.H., Rimondini R., Hansson A.C., Heileg M. CRH signaling and the dark side of addiction: long-lasting hyper-reactivity to stress in animals with a history of ethanol dependence. Neuropsychopharmacology 2006, 31:S208.
208. Sommer W.H., Rimondini R., Hansson A.C., Hipskind P.A., Gehlert D.R., Barr C.S., et al. Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala Crhr1 expression following a history of dependence. Biol Psychiatry 2008, 63:139-145.
209. Southwick S.M., Morgan C.A., Charney D.S., High J.R. Yohimbine use in a natural setting: effects on posttraumatic stress disorder. Biol Psychiatry 1999, 46:442-444.
210. Sotres-Bayon F., Cain C.K., LeDoux J.E. EBrain mechanisms of fear extinction: historical perspectives on the contribution of prefrontal cortex. Biol Psychiatry 2006, 60(4):329-336.
211. Steckler T., Dautzenberg F.M. Corticotropin-releasing factor receptor antagonists in affective disorders and drug dependence-an update. CNS Neurol Disord Drug Targets 2006, 5:147-165.
212. Stein M.B. Neurobiological perspectives on social phobia: from affiliation to zoology. Biol Psychiatry 1998, 44:1277-1285.
213. Stinus L., Cador M., Zorrilla E.P., Koob G.F. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 2005, 30:90-98.
214. Stout S.C., Mortas P., Owens M.J., Nemeroff C.B., Moreau J. Increased corticotropin-releasing factor concentrations in the bed nucleus of the stria terminalis of anhedonic rats. Eur J Pharmacol 2000, 401:39-46.
215. Strohle A., Holsboer F. Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry 2003, 36(Suppl 3):S207-214.
216. Sullivan R.M., Holman P.J. Transitions in sensitive period attachment learning in infancy: the role of corticosterone. Neurosci Biobehav Rev 2010, 34:835-844.
217. Surget A., Saxe M., Leman S., Ibarguen-Vargas Y., Chalon S., Griebel G., et al. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry 2008, 64:293-301.
218. Sweetser S., Camilleri M., Linker Nord S.J., Burton D.D., Castenada L., Croop R., et al. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?. Am J Physiol Gastrointest Liver Physiol 2009, 296:G1299-1306.
219. Swiergiel A.H., Zhou Y., Dunn A.J. Effects of chronic footshock, restraint and corticotropin-releasing factor on freezing, ultrasonic vocalization and forced swim behavior in rats. Behav Brain Res 2007.
220. Swinny J.D., O'Farrell E., Bingham B.C., Piel D.A., Valentino R.J., Beck S.G. Neonatal rearing conditions distinctly shape locus coeruleus neuronal activity, dendritic arborization, and sensitivity to corticotrophin-releasing factor. Int J Neuropsychopharmacol 2010, 13:515-525.
221. Tache Y. Corticotropin releasing factor receptor antagonists: potential future therapy in gastroenterology?. Gut 2004, 53:919-921.
222. Tache Y., Martinez V., Wang L., Million M. CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br J Pharmacol 2004, 141:1321-1330.
223. Tache Y., Million M., Nelson A.G., Lamy C., Wang L. Role of corticotropin-releasing factor pathways in stress-related alterations of colonic motor function and viscerosensibility in female rodents. Gend Med 2005, 2:146-154.
224. Takahashi L.K. Role of CRF(1) and CRF(2) receptors in fear and anxiety. Neurosci Biobehav Rev 2001, 25:627-636.
225. Takamori K., Kawashima N., Chaki S., Nakazato A., Kameo K. Involvement of corticotropin-releasing factor subtype 1 receptor in the acquisition phase of learned helplessness in rats. Life Sci 2001, 69:1241-1248.
226. Todorovic C., Radulovic J., Jahn O., Radulovic M., Sherrin T., Hippel C., et al. Differential activation of CRF receptor subtypes removes stress-induced memory deficit and anxiety. Eur J Neurosci 2007, 25:3385-3397.
227. Treutlein J., Kissling C., Frank J., Wiemann S., Dong L., Depner M., et al. Genetic association of the human corticotropin releasing hormone receptor 1 (CRHR1) with binge drinking and alcohol intake patterns in two independent samples. Mol Psychiatry 2006, 11:594-602.
228. Tyrka A.R., Carpenter L.L., McDougle C.J., Kirwin P.D., Owens M.J., Nemeroff C.B., et al. Increased cerebrospinal fluid corticotropin-releasing factor concentrations during tryptophan depletion in healthy adults. Biol Psychiatry 2004, 56:531-534.
229. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981, 213:1394-1397.
230. Vythilingam M., Anderson G.M., Owens M.J., Halaszynski T.M., Bremner J.D., Carpenter L.L., et al. Cerebrospinal fluid corticotropin-releasing hormone in healthy humans: effects of yohimbine and naloxone. J Clin Endocrinol Metab 2000, 85:4138-4145.
231. Walker D.L., Davis M. Light-enhanced startle: further pharmacological and behavioral characterization. Psychopharmacology (Berl) 2002, 159:304-310.
232. Walker D.L., Davis M. The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol Biochem Behav 2002, 71:379-392.
233. Walker D.L., Davis M. Role of the extended amygdala in short-duration versus sustained fear: a tribute to Dr. Lennart Heimer. Brain Struct Funct 2008, 213:29-42.
234. Walker D.L., Toufexis D.J., Davis M. Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol 2003, 463:199-216.
235. Walker D.L., Yang Y., Ratti E., Corsi M., Trist D., Davis M. Differential effects of the CRF-R1 antagonist GSK876008 on fear-potentiated, light- and CRF-enhanced startle suggest preferential involvement in sustained vs phasic threat responses. Neuropsychopharmacology 2009, 34:1533-1542.
236. Weninger S.C., Dunn A.J., Muglia L.J., Dikkes P., Miczek K.A., Swiergiel A.H., et al. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc Natl Acad Sci USA 1999, 96:8283-8288.
237. Winslow J.T., Insel T.R. Serotonergic and catecholaminergic reuptake inhibitors have opposite effects on the ultrasonic isolation calls of rat pups. Neuropsychopharmacology 1990, 3:51-59.
238. Winslow J.T., Insel T.R. Serotonergic modulation of the rat pup ultrasonic isolation call: studies with 5HT1 and 5HT2 subtype-selective agonists and antagonists. Psychopharmacology 1991, 105:513-520.
239. Winslow J.T., Insel T.R., Trullas R., Skolnick P. Rat pup isolation calls are reduced by functional antagonists of the NMDA receptor complex. Eur J Pharmacol 1990, 190:11-21.
240. Winslow J.T., Newman J.T., Insel T.R. CRH and alpha-helical-CRH modulate behavioral measures of arousal in monkeys. Pharmacol Biochem Behavior 1989, 32:919-926.
241. Wood G.E., Norris E.H., Waters E., Stoldt J.T., McEwen B.S. Chronic immobilization stress alters aspects of emotionality and associative learning in the rat. Behav Neurosci 2008, 122:282-292.
242. Yehuda R., Flory J.D. Differentiating biological correlates of risk, PTSD, and resilience following trauma exposure. J Trauma Stress 2007, 20:435-447.
243. Young E.A., Abelson J.L., Cameron O.G. Effect of comorbid anxiety disorders on the hypothalamic-pituitary-adrenal axis response to a social stressor in major depression. Biol Psychiatry 2004, 56:113-120.
244. Zhao Y., Valdez G.R., Fekete E.M., Rivier J.E., Vale W.W., Rice K.C., et al. Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats. J Pharmacol Exp Ther 2007, 323:846-854.
245. Zorrilla E.P., Reinhardt L.E., Valdez G.R., Inoue K., Rivier J.E., Vale W.W., et al. Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity. J Pharmacol Exp Ther 2004, 310:1027-1034.
246. Zorrilla E.P., Valdez G.R., Nozulak J., Koob G.F., Markou A. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 2002, 952:188-199.
247. Zurita A., Martijena I., Cuadra G., Brandão M.L., Molina V. Early exposure to chronic variable stress facilitates the occurrence of anhedonia and enhanced emotional reactions to novel stressors: reversal by naltrexone pretreatment. Behav Brain Res 2000, 117:163-171.